| Nome |
# |
|
Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation, file e27ce428-a144-2581-e053-d805fe0acbaa
|
1.977
|
|
Use of sodium hyaluronate and synthetic amino acid precursors of collagen for the symptomatic treatment of mucositis in patients undergoing haematopoietic stem cell transplants, file e27ce42a-9cb1-2581-e053-d805fe0acbaa
|
803
|
|
Extracellular vesicles as potential biomarkers of acute graft-vs.-host-disease, file e27ce42b-fd78-2581-e053-d805fe0acbaa
|
665
|
|
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors, file e27ce42c-b4b4-2581-e053-d805fe0acbaa
|
658
|
|
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs., file e27ce428-b439-2581-e053-d805fe0acbaa
|
624
|
|
An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation, file e27ce42f-2dc6-2581-e053-d805fe0acbaa
|
513
|
|
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives, file e27ce42e-9d5b-2581-e053-d805fe0acbaa
|
494
|
|
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation, file e27ce42c-0540-2581-e053-d805fe0acbaa
|
408
|
|
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma., file e27ce426-fca2-2581-e053-d805fe0acbaa
|
395
|
|
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma, file e27ce427-77e8-2581-e053-d805fe0acbaa
|
344
|
|
Biomarkers for acute and chronic graft versus host disease: state of the art, file e27ce430-eb13-2581-e053-d805fe0acbaa
|
258
|
|
Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients, file e27ce42d-4424-2581-e053-d805fe0acbaa
|
243
|
|
Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia, file e27ce428-a964-2581-e053-d805fe0acbaa
|
235
|
|
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo, file e27ce426-bcf9-2581-e053-d805fe0acbaa
|
232
|
|
CLINICAL IMPACT OF IMMUNOPHENOTYPIC REMISSION AFTER
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MULTIPLE MYELOMA, file e27ce427-4c29-2581-e053-d805fe0acbaa
|
205
|
|
Trichoderma species fungemia after high-dose chemotherapy and autologous stem cell transplantation: a case report, file e27ce428-b44a-2581-e053-d805fe0acbaa
|
192
|
|
The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors, file e27ce42b-f194-2581-e053-d805fe0acbaa
|
191
|
|
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma, file e27ce426-ff25-2581-e053-d805fe0acbaa
|
179
|
|
Restoring natural killer cell immunity against multiple myeloma in the era of new drugs, file e27ce42c-a9c6-2581-e053-d805fe0acbaa
|
176
|
|
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma, file e27ce427-4b8d-2581-e053-d805fe0acbaa
|
165
|
|
Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation., file e27ce42c-32ce-2581-e053-d805fe0acbaa
|
161
|
|
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice, file e27ce430-d7e2-2581-e053-d805fe0acbaa
|
160
|
|
Ruxolitinib in steroid refractory graft-vs.-host disease: A case report, file e27ce429-fbaf-2581-e053-d805fe0acbaa
|
158
|
|
Role of allogeneic stem cell transplantation in multiple myeloma, file e27ce426-b953-2581-e053-d805fe0acbaa
|
156
|
|
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation, file e27ce42c-9969-2581-e053-d805fe0acbaa
|
156
|
|
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the italian bone marrow donor registry., file e27ce426-fffb-2581-e053-d805fe0acbaa
|
151
|
|
ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ADULTS WITH MYELODYSPLASTIC SYNDROMES (MDS): RELEVANCE OF PRE-TRANSPLANT DISEASE STATUS., file e27ce426-fa63-2581-e053-d805fe0acbaa
|
146
|
|
Topical tacrolimus and periodontal therapy in the management of a case of oral chronic GVHD characterized by specific gingival localization., file e27ce426-f40f-2581-e053-d805fe0acbaa
|
141
|
|
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma, file e27ce42c-91d4-2581-e053-d805fe0acbaa
|
137
|
|
'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO), file e27ce42c-b1c8-2581-e053-d805fe0acbaa
|
137
|
|
IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA, file e27ce427-0a2b-2581-e053-d805fe0acbaa
|
135
|
|
Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma, file e27ce42c-7b37-2581-e053-d805fe0acbaa
|
128
|
|
Role of allogeneictransplantation in multiple myeloma in the era of new drugs., file e27ce426-d63f-2581-e053-d805fe0acbaa
|
125
|
|
Late-Onset Hepatic Veno-Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide, file e27ce42c-5ec5-2581-e053-d805fe0acbaa
|
124
|
|
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives, file e27ce42c-54ed-2581-e053-d805fe0acbaa
|
100
|
|
Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation, file e27ce42d-4428-2581-e053-d805fe0acbaa
|
90
|
|
IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA, file e27ce427-0a2d-2581-e053-d805fe0acbaa
|
82
|
|
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy, file e27ce431-120a-2581-e053-d805fe0acbaa
|
81
|
|
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting
in Newly Diagnosed Myeloma, file e27ce427-0a2c-2581-e053-d805fe0acbaa
|
76
|
|
null, file e27ce431-0f11-2581-e053-d805fe0acbaa
|
72
|
|
Extracellular Vesicles After Allogeneic Hematopoietic Cell Transplantation: Emerging Role in Post-Transplant Complications, file e27ce431-0d6d-2581-e053-d805fe0acbaa
|
71
|
|
CMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins, file e27ce432-759f-2581-e053-d805fe0acbaa
|
63
|
|
Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience, file e27ce434-be3b-2581-e053-d805fe0acbaa
|
61
|
|
GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS, file e27ce434-846f-2581-e053-d805fe0acbaa
|
56
|
|
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma, file e27ce434-fc96-2581-e053-d805fe0acbaa
|
48
|
|
Effect of in vivo T-cell depletion with ATG on cytomegalovirus (CMV) induced antileukemic effect in patients with
acute myeloid leukemia (AML) receiving grafts from unrelated donors., file e27ce427-4b8f-2581-e053-d805fe0acbaa
|
40
|
|
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation, file e27ce432-4ba4-2581-e053-d805fe0acbaa
|
38
|
|
Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease After Haploidentical Stem Cell Transplantation and Post-Transplant Cyclophosphamide, file e27ce435-179a-2581-e053-d805fe0acbaa
|
38
|
|
ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA, file e27ce426-ff24-2581-e053-d805fe0acbaa
|
31
|
|
Optimal delivery of follow-up care after allogeneic hematopoietic stem-cell transplant: Improving patient outcomes with a multidisciplinary approach, file e27ce430-ff5d-2581-e053-d805fe0acbaa
|
28
|
|
Treatment of symptomatic oral mucositis with sodium hyaluronate and synthetic amino acid precursors of collagen in patients undergoing haematopoietic stem cell transplantation, file e27ce42d-80cd-2581-e053-d805fe0acbaa
|
27
|
|
ROLE OF ALLOGRAFTING IN ACUTE LYMPHOBLASTIC LEUKEMIA: A 12 YEAR EXPERIENCE, file e27ce427-0a2a-2581-e053-d805fe0acbaa
|
25
|
|
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma, file e27ce42c-9e99-2581-e053-d805fe0acbaa
|
24
|
|
HLA-haploidentical allografting with high-dose post-transplant cyclophosphamide: clinical outcomes and immunereconstitution., file e27ce426-9e06-2581-e053-d805fe0acbaa
|
23
|
|
Evolving therapeutic approaches for older patients with acute myeloid leukemia in 2021, file e27ce434-db3d-2581-e053-d805fe0acbaa
|
18
|
|
Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience, file e27ce435-5a87-2581-e053-d805fe0acbaa
|
18
|
|
Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia, file ac5f7ed1-be73-4a23-8cb4-9011922e2ca7
|
15
|
|
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus Acute Lymphoblastic Leukemia study, file e27ce434-ea9f-2581-e053-d805fe0acbaa
|
15
|
|
Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting, file e27ce42d-4426-2581-e053-d805fe0acbaa
|
14
|
|
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives, file e27ce42f-74db-2581-e053-d805fe0acbaa
|
13
|
|
HSC transplant: role of amino acid substitutions in antigen binding sites, file e27ce435-5f62-2581-e053-d805fe0acbaa
|
12
|
|
Expert opinion on emerging drugs for lung chronic graft-versus-host disease, file 1407f3b4-d9d6-4057-9d1b-367c9425641a
|
10
|
|
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus Acute Lymphoblastic Leukemia study, file e27ce435-595c-2581-e053-d805fe0acbaa
|
10
|
|
Impact of allogeneic stem cell transplantation on thyroid function, file f4c61485-9034-4e14-8475-6c9d017dc79a
|
9
|
|
Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation, file 9f17cdd7-9e31-4c4f-b508-b49ef9d8ba5c
|
7
|
|
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation, file e27ce430-1511-2581-e053-d805fe0acbaa
|
6
|
|
Bacterial Bloodstream Infections after Allogeneic Hematopoietic Stem Cell Transplantation: Etiology, Risk Factors and Outcome in a Single-Center Study, file d7cc8ce3-d1c4-4357-bb90-8e4cc8e06c37
|
5
|
|
Extracellular vesicles as potential biomarkers of acute graft-vs.-host-disease, file e27ce432-5b20-2581-e053-d805fe0acbaa
|
5
|
|
Oral health status after hematopoietic stem cell transplantations: Outcomes from an adult Italian population, file 1e1b8014-250c-4085-84c8-8d45773118fe
|
4
|
|
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study, file 617ee443-b5f2-40a0-9391-f8b024f2fc2b
|
4
|
|
Cost-Effectiveness of Targeted Prophylaxis among Allogenic Stem Cell Transplant Recipients, file cc4901a4-08c3-4121-9e40-5a1c351b64dd
|
4
|
|
Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role?, file e27ce435-2885-2581-e053-d805fe0acbaa
|
4
|
|
Graft-Versus-Host Disease Prophylaxis with Antithymocyte Globulin in Patients Receiving Stem Cell Transplantation from Unrelated Donors: An Observational Retrospective Single-Center Study, file e9395fe6-0c2d-4d7f-ac92-1459001509dd
|
4
|
|
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes, file 2cc9cebe-92b2-40dc-85b6-ae41d84f0ec5
|
3
|
|
Trapianto di CSE: ruolo delle sostituzioni aminoacidiche nei siti di legame dell’antigene, file 3fe5b6ea-acfb-4733-8a0c-b8c127aff43f
|
3
|
|
null, file e27ce427-02f6-2581-e053-d805fe0acbaa
|
3
|
|
Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting, file e27ce42e-38b6-2581-e053-d805fe0acbaa
|
3
|
|
Trapianto di CSE: ruolo delle sostituzioni aminoacidiche nei siti di legame dell’antigene, file 5845e105-7295-4017-8318-a441f4c537d5
|
2
|
|
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study, file 87d1ea7d-e630-4d39-b18f-9b16872b54e6
|
2
|
|
Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological Malignancies, file e27ce426-d5d3-2581-e053-d805fe0acbaa
|
2
|
|
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study, file 0708a2ca-0a2d-406d-8c65-0346a6ff27da
|
1
|
|
Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options, file 4b66cb23-dff1-466b-877b-64661647ae65
|
1
|
|
A comparison of allografting with autografting for newly diagnosed myeloma, file e27ce426-ab5e-2581-e053-d805fe0acbaa
|
1
|
|
New drugs for treatment of multiple myeloma, file e27ce426-aeb0-2581-e053-d805fe0acbaa
|
1
|
|
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation, file e27ce426-b01a-2581-e053-d805fe0acbaa
|
1
|
|
Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients, file e27ce42c-2944-2581-e053-d805fe0acbaa
|
1
|
| Totale |
12.247 |